Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Ne…

IgA reductions sustained at 12 weeks after a single dose of JADE101>70% IgA reductions projected at steady state with a ...

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid ...

Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor typesManageable tolerability confirmed across ...
ascopubs.org

Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results.

Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma ...
UUHC Health Feed

Phase 1 Clinical Trials

Huntsman Cancer Institute at the University of Utah stands at the forefront of innovative cancer research and treatment. Phase 1 clinical trials are key to finding better ways to treat cancer safely ...
Fred Hutch

Phase 1 Clinical Trials Are an Essential Step in Advancing the Development of New Cancer Therapies

Fred Hutchinson Cancer Center leads the way when it comes to offering eligible patients alternative options when conventional therapies no longer work. With more than two dozen phase 1 clinical trials ...

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at ...

Orion Oyj: Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours

EEST Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid tumours ...
The Manila Times

ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026

Updateddata across two dose levels of 200 mW/cm and 400 mW/cmin LA-PDAC trialshow71% (5/7) patients resected following VTP with a consistent and well-tolerated safety profile- ...
ascopubs.org

First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2 ...

A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM). This is an ASCO Meeting ...